See editorial on page 400. U pper gastrointestinal bleeding (UGIB) is a common cause of admission to hospital worldwide. The incidence in the United Kingdom is 103-172 per 100,000 adults per year with an associated mortality of 8%-14%. [1] [2] [3] Antithrombotic agents (ATs), comprised of antiplatelet and anticoagulant medications, have been identified as a significant risk factor for UGIB. [4] [5] [6] However, there are currently very few studies that specifically report on AT use and their effect on clinically relevant UGIB outcomes. A UK UGIB audit in 2007 reported no increase in rebleeding for patients taking aspirin, warfarin, clopidogrel, or heparin. 3 Other retrospective studies have suggested no increased mortality in patients with UGIB who had been taking warfarin or certain other AT medications. 7, 8 In managing UGIB, clinicians can use a wide range of risk assessment scores to better predict clinically relevant outcomes, which include mortality, need for hospitalbased intervention, rebleeding, and length of hospital stay. [9] [10] [11] [12] [13] [14] However, none of these risk assessment scores account for AT use. Additionally, endoscopists may have concerns about undertaking endoscopic therapy in patients on AT medications because of potential complications. The aim of this prospective international study was to determine if there is an association between AT use and predefined clinically relevant outcomes in patients presenting with high-risk UGIB.
Methods
The study was undertaken in 8 centers: Yale New Haven Hospital (United States), Glasgow Royal Infirmary (Scotland), Royal Cornwall Hospital (England), Odense University Hospital (Denmark), Singapore General Hospital (Singapore), Dunedin Hospital (New Zealand), Saint John's Health Care (Ontario, Canada), and Humanitas Hospital (Milan, Italy) This is a subgroup analysis from a study investigating the utility of scoring systems in UGIB. 15 
Inclusion/Exclusion Criteria
All patients who presented with acute UGIB as defined by hematemesis, coffee ground vomit, or melena were included. Only patients who required endoscopic therapy ("high risk") were assessed in this study. Patients already in hospital for another reason who developed UGIB were excluded.
Data Collection
Data were prospectively collected from March 2014 to March 2015 on unselected, consecutive patients presenting with UGIB. Two centers (Ontario and Milan) provided nonconsecutive data.
A dedicated member of the local study team recorded data including AT use being low-dose aspirin, thienopyrimidines, warfarin, low-molecular-weight heparin, thrombin inhibitors, and Factor Xa inhibitors; patient comorbidities and characteristics; laboratory results and hemodynamic parameters required to calculate the full Rockall score (FRS), Glasgow Blatchford Score, AIMS65 (albumin, international normalized ratio, mental status, systolic blood pressure, age >65) score, American Society of Anesthesiologists (ASA) score 16 ; endoscopic findings; and the clinically relevant outcomes of (1) in-patient and 30-day mortality (bleeding-related and all-cause), (2) rebleeding within 7 days, (3) need for surgery or interventional radiology (IR), (4) units of blood received, and (5) length of hospital stay.
Definitions
AT use was defined by the identification of an AT drug prescribed up to admission, but did not include details on length of AT treatment or compliance. Lowdose aspirin was considered to be a dose of 325 mg. Rebleeding was defined as per Laine et al (Supplementary Table 1) . 17 
Patient Management
In all centers, endoscopy was performed within 24 hours for all patients admitted with UGIB where possible. For nonvariceal bleeding, the policy in all centers (other than Yale) was to apply endoscopic therapy for active bleeding, visible vessels, and adherent clots (Forrest classifications 1a and Ib, IIa and IIb) 18 using injection therapy, thermal contact and/or clips, but not adrenaline alone. [19] [20] [21] At Yale, the endoscopist determined whether to treat adherent clots. Patients with suspected variceal hemorrhage were to be treated with vasopressors and antibiotics before endoscopy 20, 22 What You Need to Know Background AT agents are risk factors for upper gastrointestinal bleeding but their effect on outcome and risks of endotherapy in such high-risk patients is largely unknown.
Findings
Patients who take ATs have lower mortality because of gastrointestinal bleeding, shorter hospital stays, with similar rates of rebleeding, surgery, and transfusions compared with patients not on these agents.
Implications for patient care
Endoscopists should be reassured that endotherapy in these patients is safe. Further consideration as to the benefits, rather than the complications, of AT use in selected patients is required.
followed by band ligation, injection of tissue glue AE transjugular intrahepatic portosystemic stent-shunt in cases of esophageal or gastric variceal bleeding, respectively. 20, 23 Red cell transfusion was administered at a hemoglobin threshold of 70-80 g/L or as guided by the clinician in severe hemorrhage. 23, 24 Following endoscopy, all centers had a policy to administer high-dose intravenous proton pump inhibitors to patients with high-risk ulcer stigmata who required endoscopic therapy and to other selected patients depending on clinical judgment. 25 Policy on reintroduction of AT medication is summarized in Supplementary Appendix 1.
Statistical Analysis
Pearson chi-square test and Fischer exact test were used to compare proportions. The Mann-Whitney U test was used to compare means. A 2-tailed significance level of 5% was used in all comparisons. Logistic regression analyses were used to estimate the association between use of AT drugs and all-cause mortality following adjustment for differences in patients' characteristics. Further explanation is detailed in Supplementary Appendix 2.
Based on unpublished data from a previous study, 26 the overall mortality rate among patients treated with endotherapy for UGIB was 8.8%. Previous data from a UK audit found that presence of coagulopathy was associated with a 5-fold increase in mortality. 27 Therefore, assuming a mortality rate among non-AT users requiring endoscopic therapy of 7.5%, a mortality rate among AT users requiring endoscopic therapy of 15%, and a power of 80%, we determined that we required a sample size of 608 patients. Missing data were handled using listwise deletion, otherwise known as complete case analysis. 28 
Results

Patient Numbers
Out of 3154 patients presenting with UGIB during the period of inclusion, 619 (19.6%) required endotherapy and were considered for the study. Data on AT use were unavailable in 51 (8%) patients; therefore, 568 patients were included in the final analyses. Patient numbers, rates of endotherapy, and recruitment per center are provided in Supplementary Table 2 . A total of 537 (94.5%) patients had follow-up recorded; 513 (90.3%) were followed up for 30 days, with the rest having in-patient follow-up. There was no difference in the 30-day follow-up between those taking and those not taking AT drugs (226 [89%] vs 287 [91%]). A total of 253 (44%) patients were taking an AT drug at presentation, with 63 (25%) prescribed more than 1 drug. Table 1 shows the number of patients per individual AT.
Patient Characteristics
Patients taking an AT drug were older with a mean age of 74 versus 60 years (P < .001); had a higher incidence of ischemic heart disease (IHD; 102 [40%] vs 29 [9%]; P < .001) and heart failure (35 [14%] vs 16 [5%]; P < .001); had a higher mean ASA score (2.9 vs 2.6; P < .001), mean FRS (5.2 vs 4.2; P < .0001), and mean AIMS65 score (1.5 vs 1.2; P < .0001); but had lower mean heart rate (90 vs 98 beats/min; P < .0001). There were no significant differences between groups with regard to gender ( The highest proportions of missing data (Table 1 ) were 10% for AIMS65 and 8% for FRS. However, there were no significant differences in mortality rates (3.4% vs 9.0%) or rate of AT use (49% vs 44%) between patients with versus those without missing data for AIMS65. Similarly, there were no differences in these for FRS (6.5% vs 8.6%) and (50% vs 44%), respectively.
Endoscopic Findings
Endoscopy was performed within 24 hours in 394 (69%) patients corresponding to a median time to endoscopy of 13 hours (95% confidence interval [CI], 3-59) with no difference between users and nonusers of ATs (12 hours [95% CI, 3-61] vs 14 hours [95% CI, 3-59], respectively). Overall, 237 (42%) patients had peptic ulcer bleeding (PUB) and 123 (22%) had variceal bleeding. PUB was more common in AT users compared with non-AT users (125 [50%] vs 112 [36%]; P ¼ .001), whereas variceal bleeding was less common in AT users (20 [8%] vs 103 [33%]; P < .001). Although patients taking AT drugs were more likely to have PUB than variceal bleeding (P < .001), there was no significant difference between rates of bleeding etiologies in the non-AT group (Table 2) . When including patients from the primary dataset who were diagnosed with PUB (n ¼ 555), there was no difference in the proportion of patients receiving endoscopic therapy between groups (non-AT 112/285 [39%] vs AT 125/270 [46%]; P ¼ .10). 
Clinically Relevant Outcomes
More than 1 AT-intake (n ¼ 63) 
NOTE. Data are number of patients (%). There were missing values for ASA score (n ¼ 4), malignancy (n
, and length of hospitalization (n ¼ 8). AIMS65, albumin, international normalized ratio, mental status, systolic blood pressure, age over 65; ASA, American Society of Anesthesiologists; AT, antithrombotic; BP, blood pressure; CI, confidence interval; GBS, Glasgow Blatchford Score; IHD, ischemic heart disease; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist. 
Regression Analysis
Following adjustment for age, ASA score, and variceal bleeding, use of AT drugs was still associated with lower 30-day mortality (OR, 0.26; 95% CI, 0.12-0.57; P ¼ .001; n ¼ 564) (Table 4 ). This was also the case when only including patients undergoing endoscopy within 24 hours (OR, 0.24; 95% CI, 0.09-0.67; P ¼ .006; n ¼ 391). When cirrhosis was incorporated in the regression model instead of variceal bleeding, this did not change the identified association between AT use and risk of death (adjusted OR, 0.29; 95% CI, 0.13-0.66; P ¼ .003; n ¼ 564). Goodness-of-fit for the model (Pearson chi-square, 440.76; P ¼ .9997) showed no indication of poor fit in the initial or final regression model.
By incorporating an interaction term in the main regression analysis, there was no evidence that the identified association between AT use and mortality was explained by an interaction between AT use and cirrhosis (interaction term: OR, 1.04; 95% CI, 0.12-9.34; P ¼ .969). The results were similar when the interaction term was included in the regression model where cirrhosis was incorporated instead of variceal bleeding (interaction term: OR, 0.63; 95% CI, 0.07-6.13; P ¼ .69). A sensitivity analysis was also performed by excluding patients with cirrhosis. This did not change the identified association between AT use and mortality (adjusted OR of AT use on mortality, 0.29; 95% CI, 0.12-0.72; P ¼ .008). An interaction term in the model was used to assess a possible interaction between the type of AT used and mortality; however, there was no evidence of statistical interaction (interaction term: OR, 1.27; 95% CI, 0.87-1.84; P ¼ .219). Data were available on all variables included in the model for 99% (564/568) of patients. Therefore, we believe that use of complete case analysis is an acceptable approach in this context. 28 
Discussion
This international multicenter study assessed the effect of pre-existing use of AT drugs on clinically relevant outcomes in patients who present with UGIB and require endoscopic therapy. As expected, patients taking ATs were older, had more comorbidities, lower admission hemoglobin, and were at higher risk based on standard UGIB risk stratification tools. Despite this, we found rates of rebleeding, transfusion, and need for surgery or IR to be similar for those taking and not taking AT drugs. Importantly, we also found that mortality was lower in the group taking AT medications, even after adjusting for potential confounding factors with multivariable regression analysis. Interestingly, lower bleeding-related mortality was the driver for reduced all-cause mortality in patients taking AT drugs.
It is recognized that most patients with UGIB die from non-GI-bleeding-related causes including cardiopulmonary conditions, 29 of which AT use may prevent. Because the underlying cause of death was not registered in detail, we were not able to test this hypothesis based on our dataset. Although there was no significant difference in the nonbleeding-related mortality rates between AT users (3.2%) and non-AT users (5.7%), this may be explained by low power. Residual confounding caused by differences in patients' characteristics between users and nonusers of AT medications may also affect our results. However, it could be postulated that the older, more comorbid patients who were taking AT drugs would be expected to have a higher mortality; therefore, even if our findings were caused by residual confounding, our results make it very unlikely that there is higher mortality with AT therapy. Risk stratification tools for UGIB do not take AT medication use into account, casting some doubt as to whether endoscopic therapy is safe in these patients. With iatrogenically impaired blood clotting, some may argue that endoscopic therapy is even dangerous. However, our results provide reassurance to clinicians that endoscopic therapy can be applied when indicated in patients taking ATs, without concern that it will worsen outcomes. This will help prevent unnecessary delay of treatment for those who require it. Although patients with cirrhosis generally have higher mortality and are often not prescribed AT drugs, when we adjusted for age, ASA score, variceal bleeding, and AT use, we did not find a significant association between liver cirrhosis and mortality in our data. As expected, ASA score (OR, 1.96; 95% CI, 1.31-2.94) and variceal bleeding (OR, 3.38; 95% CI, 1.52-7.51) were both associated with a significant increase in mortality. Cirrhosis is taken into consideration when calculating the ASA score and most patients with liver cirrhosis who died had variceal bleeding. However, after replacing variceal bleeding with cirrhosis in our regression model, the association between AT use and mortality was unchanged. This suggests that our main finding is not simply explained by confounding caused by cirrhosis, albeit the power for evaluating such an interaction in the regression model is low. Interestingly, anticoagulant use has previously been shown to not significantly affect outcomes of patients with cirrhosis and UGIB. 30 Similar to our results, a previous study 3 also found that rebleeding is not more frequent in patients taking AT drugs. Of the patients who rebled in our study, radiological embolization or surgery was required in a similar proportion of those taking, or not taking, AT medications. The resumption of anticoagulant medications following a UGIB is associated with a lower rate of thromboembolic events, without increased rebleeding or death, 31, 32 and similarly, discontinuation of AT therapy following acute UGIB is associated with reduced survival. 33 In addition, resumption of anticoagulants in patients with atrial fibrillation and UGIB is associated with a survival benefit. 34 Exact data on AT resumption in our group were unavailable, although our policy on reintroduction of AT medication is outlined previously. Our policy is in keeping with evidence that continuing low-dose aspirin can reduce overall mortality in patients with PUB. 35 Although these studies support our findings to a degree, they are not analogous. Our study, which incorporated a wide range of AT drugs, has specifically assessed the effect of these medications on several predefined clinical endpoints. In addition, our study included only patients with highrisk UGIB, given that only those who had endoscopic therapy were assessed, rather than all patients presenting with UGIB. AT taken (n ¼ 253)
More than 1 AT-intake (n ¼ 63)
Rebleeding 49 (17) 34 (14) NS 27 (16) 9 (15) 6 (11) 1 (14) 1 (100) 1 (14) 11 ( The strengths of this study include its prospective, international, multicenter design with a large number of unselected and (in most centers) consecutive patients, with most followed up for 30 days. There are some limitations. There were variable rates of endoscopic therapy with higher rates of intervention in 1 center (Milan). That center recorded relatively few, and nonconsecutive patients. The Forrest classification was not recorded in the dataset; however, the practice in all centers was similar with regard to indications for, and implementation of, endoscopic therapy. We had missing data for calculation of AIMS65 and FRS. However, there was no difference in mortality or rate of AT use for those with or without missing data for either score; therefore, we do not believe this affects our conclusions. Unfortunately, some data that may have been helpful to further explain our results are unavailable. This includes data on indication for AT use other than IHD, specific cause of nonbleeding mortality, compensated versus decompensated liver disease, Model for End-Stage Liver Disease and Childs Pugh scores and rates of specific therapies for variceal bleeding, and incomplete postdischarge followup in some patients. Because of small patient numbers taking each AT, we could not assess with reasonable power whether any individual AT had a stronger contribution to the mortality reduction.
Although we were not able to use a robust comorbidity index, such as the Charlson index, we did have data on the ASA score and important specific comorbidities (Table 1) . Interestingly, 22% of our patients with documented IHD were not treated with ATs, which was a consistent finding across all sites. These patients had a much higher mortality rate than IHD patients treated with ATs (21% vs 3%) and could be one of the reasons our findings do not show an association between AT use and increased mortality. This may be because of patients deemed at very high risk of UGIB not being given AT medication. Future studies should assess this important issue, which may lead to changes in clinical practice.
In conclusion, despite their older age, increased comorbidities, and after adjustment for confounding variables, patients with UGIB requiring endoscopic therapy while on AT medications had lower bleedingrelated, mortality compared with those not taking these drugs. In addition, the group taking AT medications had similar rates of rebleeding, surgery, and IR, similar number of units of red blood cell transfusions, and lower length of hospital stay compared with those not taking these drugs. Despite the known increased risk of UGIB associated with AT use, it seems that pre-existing use of these drugs is not associated with worse outcome after UGIB, and that endoscopic therapy in these patients should not be withheld. Further studies in comparable patients are required to determine whether previous use of AT therapy does indeed confer a survival benefit.
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